Gateway for:

Member Countries

Production of Radionuclides and Radiopharmaceuticals

#0777


Development of Research Methods for WWR-c Nuclear Reactor Application in the Chemistry and Ecologically Sound Technology for Production of Radionuclides and Radionuclide-Based Organ-Selective Radiopharmaceuticals

Tech Area / Field

  • MED-RAD/Radiomedicine/Medicine
  • FIR-ISO/Isotopes/Fission Reactors

Status
3 Approved without Funding

Registration date
27.10.1996

Leading Institute
Karpov Institute of Physical Chemistry (2), Russia, Kaluga reg., Obninsk

Supporting institutes

  • Medical Radiological Scientific Center, Russia, Kaluga reg., Obninsk\nFEI (IPPE), Russia, Kaluga reg., Obninsk

Collaborators

  • Hans Wälischmiller GmbH, Germany, Markdorf\nGamma-Service / Isotopen-& Strahlentechnik GmbH, Germany, Leipzig\nSandia National Laboratories, USA, NM, Albuquerque

Project summary

The Project is a program of basic and experimental research which aims at studying the possibilities and developing the application methods of the WWR-c nuclear reactor and reactor-based technological facilities for producing medical radionuclides and radionuclide-based radiopharmaceuticals (RPhCs) for diagnostics and treatment of serious diseases. The Project is undertaken under conversion program and designed especially for researchers in physics and chemistry of fissile materials and nuclear reactor engineering who were earlier involved in defense-related activities.

The Project is urgent first of all because the demands in RPhCs in Russia are met, but far from being complete. This equally relates to both the quantity and assortment. The consequences of the Chernobyl as well as of the other radiation accidents raise even higher the importance of the works to be carried out in this direction under the Project.

The Project anticipates complex physical and chemical research including the solution of all the problems concerning the RPhC production. To these belong modification of the methods for nuclear reactor application in radionuclide production with efficient protection from radioactive iodine release into the environment, investigation of the chromatographic recovery methods for high purity 99mTc, development of the synthetic methods for organ-selective carrier-molecules and complexons used as radionuclide organic applications, study of the efficient techniques for carrier-molecule labeling with radionuclides, preclinical and clinical tests of new RPhCs.

The three-year Project performance will result in the development and production of 14 RPhCs in trial lots containing reactor (iodine-131, samarium-153, technitium-99m, rhenium-186, rhenium-188) and cyclotron - generated radionuclides (iodine - 123, gallium-67). The main attention will be paid to the elaboration of RPhCs for diagnostics of heart and cerebrum which are widely used in the developed countries but they are absent in Russia. Among them are such as w-(p-iodophenyl) pentadecanoic acid, N-isopropyl p-iodoamphetamine, w-iodobenzylguanidine with 132J, tetraphosmine with 99mTc. The list of RPhCs to be worked at under this Project is agreed on with the Ministry for Healthcare of the Russian Federation.

Following the preliminary estimates, the Project execution will yield annual RPhC production which amounts US $ 4 000 000. Therefore, the Project will make the basis of the long-term financial assistance to the researchers and engineers under conversion program which is conceived to change the defense-related activities into civil-oriented scope of works.

The Project has an international significance because it anticipates the use of engineering facilities and intellectual potentialities of the research teams in Russia, Germany, Usa.

The foreign partners are as follows: Hans Walischmiller GmbH (Rossendorf, Germany), Sandia National Laboratories (the US Department of Energy). They will be responsible for development of the hot cell equipment, radiation protection systems for the whole nuclear complex, sterility of the rooms and instrumentation to control the parameters of technological processes. A new design of 99mTc generators and radioactive iodine-labeled RPhCs will be tested in Germany. Close business relations have already been established with the German and American partners, and the contract has been recently for delivery of the appropriate equipment and reconstruction of the available production facilities.


Back